ADAR1 Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

ADAR1 Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$150K	Buy	41,000 +6,000	+17%	+$20K	0.01%	254
2026 Q1	$107K	Hold	35,000	–	–	0.01%	286
2025 Q4	$143K	Hold	35,000	–	–	0.01%	239
2025 Q3	$171K	Hold	35,000	–	–	0.02%	184
2025 Q2	$177K	Buy	35,000 +20,000	+133%	+$98.3K	0.03%	158
2025 Q1	$79.3K	Hold	15,000	–	–	0.01%	172
2024 Q4	$101K	Hold	15,000	–	–	0.02%	181
2024 Q3	$98.8K	Buy	+15,000	New	+$108K	0.02%	188

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ADAR1 Capital Management's RXRX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 17% in Q2 2026, buying an estimated $20K and bringing the position to 41,000 shares worth $150K. The position accounts for 0.01% of the portfolio, ranked #254.

ADAR1 Capital Management first reported a position in RXRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $177K in Q2 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

ADAR1 Capital Management held 41,000 shares of Recursion Pharmaceuticals worth $150K as of Q2 2026.
ADAR1 Capital Management bought 6,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $20K.
Recursion Pharmaceuticals made up 0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #254 holding.
ADAR1 Capital Management first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
ADAR1 Capital Management's Recursion Pharmaceuticals position peaked at $177K in Q2 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.